Javier Leon

List of Publications by Year
in descending order

88 papers	4,094 citations	117625 34 h-index	123424 61 g-index
93 all docs	93 docs citations	93 times ranked	6139 citing authors

#	Article	IF	Citations
1	A novel role of MNT as a negative regulator of REL and the NF-Î°B pathway. Oncogenesis, 2021, 10, 5.	4.9	1
2	The Multiple Faces of MNT and Its Role as a MYC Modulator. Cancers, 2021, 13, 4682.	3.7	6
3	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Biomedicine and Pharmacotherapy, 2021, 144, 112330.	5.6	4
4	The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells. Journal of Biological Chemistry, 2020, 295, 2001-2017.	3.4	10
5	Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. Scientific Reports, 2019, 9, 16495.	3.3	27
6	MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes, 2019, 10, 244.	2.4	136
7	Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27. Scientific Reports, 2019, 9, 18693.	3.3	40
8	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene, 2017, 36, 1733-1744.	5.9	48
9	CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. Oncotarget, 2017, 8, 29679-29698.	1.8	10
10	CD3Îµ recruits Numb to promote TCR degradation. International Immunology, 2016, 28, 127-137.	4.0	8
11	NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells. Cancer Letters, 2016, 375, 92-99.	7.2	6
12	MXD1 localizes in the nucleolus, binds UBF and impairs rRNA synthesis. Oncotarget, 2016, 7, 69536-69548.	1.8	19
13	Myc and cell cycle control. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 506-516.	1.9	538
14	A novel mutation in ADAMTS13 of a child with Upshaw-Schulman Syndrome. Thrombosis and Haemostasis, 2014, 112, 1065-1068.	3.4	3
15	Sin3b Interacts with Myc and Decreases Myc Levels. Journal of Biological Chemistry, 2014, 289, 22221-22236.	3.4	29
16	High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. Oncotarget, 2014, 5, 4694-4708.	1.8	22
17	MYC oncogene in myeloid neoplasias. Clinical and Translational Oncology, 2013, 15, 87-94.	2.4	51
18	MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1. Oncogene, 2013, 32, 2239-2246.	5.9	54

#	ARTICLE	IF	CITATIONS
19	p21 as a Transcriptional Co-Repressor of S-Phase and Mitotic Control Genes. PLoS ONE, 2012, 7, e37759.	2.5	42
20	MYC accelerates p21^{CIP}â€induced megakaryocytic differentiation involving early mitosis arrest in leukemia cells. Journal of Cellular Physiology, 2012, 227, 2069-2078.	4.1	15
21	SKP2 Oncogene Is a Direct MYC Target Gene and MYC Down-regulates p27KIP1 through SKP2 in Human Leukemia Cells. Journal of Biological Chemistry, 2011, 286, 9815-9825.	3.4	79
22	MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib. Molecular Cancer Research, 2011, 9, 564-576.	3.4	54
23	Myc Roles in Hematopoiesis and Leukemia. Genes and Cancer, 2010, 1, 605-616.	1.9	217
24	p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer Letters, 2010, 292, 133-139.	7.2	20
25	p73 Plays a Role in Erythroid Differentiation through GATA1 Induction. Journal of Biological Chemistry, 2009, 284, 21139-21156.	3.4	16
26	Inhibition of cell differentiation: A critical mechanism for MYC-mediated carcinogenesis?. Cell Cycle, 2009, 8, 1148-1157.	2.6	54
27	HCT116 cells deficient in p21Waf1 are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. DNA Repair, 2009, 8, 390-399.	2.8	17
28	PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Letters, 2008, 270, 328-336.	7.2	18
29	Bobel-24 and Derivatives Induce Caspase-Independent Death in Pancreatic Cancer Regardless of Apoptotic Resistance. Cancer Research, 2008, 68, 6313-6323.	0.9	16
30	c-Myc Inhibits Ras-Mediated Differentiation of Pheochromocytoma Cells by Blocking c-Jun Up-Regulation. Molecular Cancer Research, 2008, 6, 325-339.	3.4	30
31	Myc Inhibits p27-Induced Erythroid Differentiation of Leukemia Cells by Repressing Erythroid Master Genes without Reversing p27-Mediated Cell Cycle Arrest. Molecular and Cellular Biology, 2008, 28, 7286-7295.	2.3	53
32	Determination of Viability of Human Cartilage Allografts by a Rapid and Quantitative Method Not Requiring Cartilage Digestion. Cell Transplantation, 2008, 17, 859-864.	2.5	10
33	p73 cooperates with Ras in the activation of MAP kinase signaling cascade. Cell Death and Differentiation, 2007, 14, 254-265.	11.2	22
34	Gene expression regulation and cancer. Clinical and Translational Oncology, 2006, 8, 780-787.	2.4	24
35	Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation-dependent mechanism. Journal of Cell Science, 2006, 119, 1746-1759.	2.0	75
36	Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc. Molecular Cancer Therapeutics, 2006, 5, 1166-1175.	4.1	11

#	Article	IF	Citations
37	Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes. Oncogene, 2005, 24, 4559-4571.	5.9	43
38	CTCF Regulates Growth and Erythroid Differentiation of Human Myeloid Leukemia Cells. Journal of Biological Chemistry, 2005, 280, 28152-28161.	3.4	76
39	Myc Antagonizes Ras-mediated Growth Arrest in Leukemia Cells through the Inhibition of the Ras-ERK-p21Cip1 Pathway. Journal of Biological Chemistry, 2005, 280, 1112-1122.	3.4	37
40	p21Cip1 and p27Kip1 Induce Distinct Cell Cycle Effects and Differentiation Programs in Myeloid Leukemia Cells. Journal of Biological Chemistry, 2005, 280, 18120-18129.	3.4	81
41	Subcellular Localization Determines the Protective Effects of Activated ERK2 against Distinct Apoptogenic Stimuli in Myeloid Leukemia Cells. Journal of Biological Chemistry, 2004, 279, 32813-32823.	3.4	51
42	Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene, 2004, 23, 7378-7390.	5.9	74
43	Kinetics ofmyc-max-madgene expression during hepatocyte proliferation in vivo: Differential regulation ofmadfamily and stress-mediated induction of c-myc. Molecular Carcinogenesis, 2004, 39, 85-90.	2.7	20
44	C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica, 2004, 89, 241-3.	3.5	15
45	Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene, 2003, 22, 351-360.	5.9	277
46	Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Molecular Cancer Therapeutics, 2003, 2, 893-900.	4.1	17
47	Identification of a Candidate Tumor-Suppressor Gene Specifically Activated during Ras-Induced Senescence. Experimental Cell Research, 2002, 273, 127-137.	2.6	58
48	Contributions of Myc to tumorigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2002, 1602, 61-71.	7.4	106
49	Functional Phosphorylation Sites in the C-Terminal Region of the Multivalent Multifunctional Transcriptional Factor CTCF. Molecular and Cellular Biology, 2001, 21, 2221-2234.	2.3	89
50	Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Research, 2001, 61, 6002-7.	0.9	94
51	H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene, 2000, 19, 783-790.	5.9	53
52	c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene, 2000, 19, 2194-2204.	5.9	58
53	Ras proteins in the control of the cell cycle and cell differentiation. Cellular and Molecular Life Sciences, 2000, 57, 1613-1636.	5.4	160
54	Myeloid Leukemia Cell Growth and Differentiation Are Independent of Mitogen-activated Protein Kinase ERK1/2 Activation. Journal of Biological Chemistry, 2000, 275, 7189-7197.	3.4	31

#	Article	IF	Citations
55	Differential expression and phosphorylation of CTCF, a c-myctranscriptional regulator, during differentiation of human myeloid cells. FEBS Letters, 1999, 444, 5-10.	2.8	31
56	Apoptosis and Mitotic Arrest Are Two Independent Effects of the Protein Phosphatases Inhibitor Okadaic Acid in K562 Leukemia Cells. Biochemical and Biophysical Research Communications, 1999, 260, 256-264.	2.1	42
57	Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1999, 10, 639-54.	0.8	5
58	Spi-1/PU.1 Proto-oncogene Induces Opposite Effects on Monocytic and Erythroid Differentiation of K562 Cells. Biochemical and Biophysical Research Communications, 1998, 252, 383-391.	2.1	19
59	Interferon Induces Up-regulation of Spi-1/PU.1 in Human Leukemia K562 Cells. Biochemical and Biophysical Research Communications, 1997, 240, 862-868.	2.1	10
60	Positive autoregulation ofrasgenes expression in fibroblasts. FEBS Letters, 1997, 416, 317-323.	2.8	5
61	Apoptosis of human myeloid leukemia cells induced by an inhibitor of protein phosphatases (okadaic) Tj ETQq1 1 0.784314 rgBT /Overlo	7.2	47
62	Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene, 1997, 14, 1315-1327.	5.9	51
63	Expression of Insulin-Like Growth Factor Receptor mRNA in Rabbit Atherosclerotic Lesions. Biochemical and Biophysical Research Communications, 1995, 209, 182-190.	2.1	16
64	Down Regulation of C-MYC and MAX Genes Is Associated to Inhibition of Protein Phosphatase 2A in K562 Human Leukemia Cells. Biochemical and Biophysical Research Communications, 1995, 215, 889-895.	2.1	18
65	Expression of apolipoprotein e in cholesterol-loaded macrophages of extrahepatic tissues during experimental hypercholesterolemia. Life Sciences, 1995, 56, 1865-1875.	4.3	5
66	Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene, 1995, 10, 1659-65.	5.9	55
67	Apolipoprotein E expression in the cerebellum of normal and hypercholesterolemic rabbits. Molecular Brain Research, 1994, 21, 115-123.	2.3	10
68	Induction of apolipoprotein E expression during erythroid differentiation of human K562 leukemia cells. Leukemia Research, 1993, 17, 771-776.	0.8	3
69	Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells. Leukemia, 1993, 7, 1824-33.	7.2	16
70	Hypercholesterolemia induces differential expression of rabbit apolipoprotein A and C genes. Atherosclerosis, 1992, 95, 95-103.	0.8	8
71	Downregulation of hepatic albumin mRNA in response to induced hypercholesterolemia in rabbits. Lipids and Lipid Metabolism, 1992, 1128, 77-82.	2.6	1
72	Foam cells from aorta and spleen overexpress apolipoprotein E in the absence of hypercholesterolemia. Biochemical and Biophysical Research Communications, 1992, 183, 514-523.	2.1	11

#	Article	IF	Citations
73	Differential expression of ras protooncogenes during in vitro differentiation of human erythroleukemia cells. Cancer Research, 1992, 52, 5979-84.	0.9	13
74	ras activation in human tumors and in animal model systems.. Environmental Health Perspectives, 1991, 93, 19-25.	6.0	29
75	Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921. Antimicrobial Agents and Chemotherapy, 1990, 34, 2016-2018.	3.2	25
76	Induction of apolipoprotein E gene expression in human and experimental atherosclerotic lesions. Biochemical and Biophysical Research Communications, 1990, 168, 733-740.	2.1	23
77	Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation?. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 6372-6376.	7.1	92
78	H-ras activation in benign and self-regressing skin tumors (keratoacanthomas) in both humans and an animal model system.. Molecular and Cellular Biology, 1988, 8, 786-793.	2.3	72
79	H-ras activation in benign and self-regressing skin tumors (keratoacanthomas) in both humans and an animal model system. Molecular and Cellular Biology, 1988, 8, 786-793.	2.3	18
80	Differential expression of the ras gene family in mice.. Molecular and Cellular Biology, 1987, 7, 1535-1540.	2.3	204
81	Differential Expression of the <i>ras</i> Gene Family in Mice. Molecular and Cellular Biology, 1987, 7, 1535-1540.	2.3	79
82	Fosfomycin Causes Transient Lysis in Escherichia coli Strains Carrying Fosfomycin-resistance Plasmids. Microbiology (United Kingdom), 1985, 131, 3255-3260.	1.8	3
83	Fosfomycin-resistance Plasmids Determine an Intracellular Modification of Fosfomycin. Microbiology (United Kingdom), 1985, 131, 1649-1655.	1.8	9
84	Structural and functional analyses of the fosfomycin resistance transposon Tn2921. Journal of Bacteriology, 1985, 162, 1061-1067.	2.2	12
85	Cloning and expression in minicells of the determinant of resistance to fosfomycin from the transposon Tn2921. Plasmid, 1984, 11, 243-247.	1.4	15
86	Fosfomycin inactivates its target enzyme in Escherichia coli cells carrying a fosfomycin resistance plasmid.. Antimicrobial Agents and Chemotherapy, 1983, 24, 276-278.	3.2	5
87	Fosfomycin resistance plasmids do not affect fosfomycin transport into Escherichia coli. Antimicrobial Agents and Chemotherapy, 1982, 21, 608-612.	3.2	15
88	MYC as therapeutic target in leukemia and lymphoma. Blood and Lymphatic Cancer: Targets and Therapy, 0, , 75.	2.7	2